JW Pharmaceutical 미래 성장

Future 기준 확인 3/6

JW Pharmaceutical (는) 각각 연간 13.3% 및 10.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 22.2% 로 예상됩니다.

주요 정보

13.3%

수익 성장률

13.2%

EPS 성장률

Pharmaceuticals 수익 성장	33.3%
매출 성장률	10.3%
향후 자기자본 수익률	22.2%
애널리스트 커버리지	Low
마지막 업데이트	22 Aug 2024

최근 미래 성장 업데이트

Recent updates

JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.

Jan 19

Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend

Dec 24

Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?

Nov 30

수익 및 매출 성장 예측

KOSE:A001060 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (KRW Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	947,450	99,050	80,900	120,150	2
12/31/2025	871,750	89,550	74,300	117,750	2
12/31/2024	802,650	78,250	53,500	80,800	2
9/30/2024	736,543	72,893	65,704	95,076	N/A
6/30/2024	742,090	35,136	91,644	120,197	N/A
3/31/2024	755,737	40,621	91,518	122,485	N/A
12/31/2023	748,527	36,489	46,452	87,157	N/A
9/30/2023	736,668	25,076	42,709	76,046	N/A
6/30/2023	722,312	51,278	29,078	58,339	N/A
3/31/2023	701,393	36,949	28,177	51,238	N/A
12/31/2022	684,351	31,892	44,412	56,764	N/A
9/30/2022	660,661	12,130	32,649	46,346	N/A
6/30/2022	639,806	8,930	37,194	50,657	N/A
3/31/2022	620,832	4,584	27,866	41,446	N/A
12/31/2021	606,585	-968	5,222	18,124	N/A
9/30/2021	581,827	-1,190	4,847	19,302	N/A
6/30/2021	569,978	-3,329	22,689	36,349	N/A
3/31/2021	560,407	-8,469	28,086	43,146	N/A
12/31/2020	547,336	-15,241	48,015	63,054	N/A
9/30/2020	516,529	-31,512	65,219	77,881	N/A
6/30/2020	512,402	-33,320	36,132	49,800	N/A
3/31/2020	510,079	-23,341	43,389	56,719	N/A
12/31/2019	511,335	-25,275	42,354	55,531	N/A
9/30/2019	524,767	-9,432	3,533	16,086	N/A
6/30/2019	538,269	-8,270	40,264	51,987	N/A
3/31/2019	536,808	-659	61,987	72,856	N/A
12/31/2018	537,182	8,057	42,829	52,110	N/A
9/30/2018	534,919	9,113	56,378	66,480	N/A
6/30/2018	521,666	12,567	N/A	35,484	N/A
3/31/2018	510,284	2,417	N/A	5,770	N/A
12/31/2017	502,919	-742	N/A	33,450	N/A
9/30/2017	490,656	14,223	N/A	36,480	N/A
6/30/2017	476,290	3,697	N/A	6,678	N/A
3/31/2017	471,517	-11,472	N/A	14,991	N/A
12/31/2016	467,465	-10,934	N/A	6,739	N/A
9/30/2016	460,523	-18,836	N/A	-799	N/A
6/30/2016	452,150	-12,991	N/A	17,745	N/A
3/31/2016	447,417	2,860	N/A	28,884	N/A
12/31/2015	434,352	1,921	N/A	-4,175	N/A
9/30/2015	447,788	1,575	N/A	8,860	N/A
6/30/2015	439,802	1,064	N/A	15,286	N/A
3/31/2015	426,011	-3,378	N/A	-12,885	N/A
12/31/2014	412,791	-2,357	N/A	7,279	N/A
9/30/2014	386,064	-2,651	N/A	6,994	N/A
6/30/2014	386,067	-2,648	N/A	-16,031	N/A
3/31/2014	395,535	3,095	N/A	16,653	N/A
12/31/2013	394,182	2,275	N/A	18,725	N/A

애널리스트 미래 성장 예측

수입 대 저축률: A001060 의 연간 예상 수익 증가율( 13.3% )이 saving rate( 2.7% 보다 높습니다. ).

수익 vs 시장: A001060 의 연간 수익( 13.3% ) KR 시장( 28.4% 보다 느리게 성장할 것으로 예상됩니다. 28.4% 연간).

고성장 수익: A001060 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: A001060 의 수익(연간 10.3% ) KR 시장( 9.4% 보다 빠르게 성장할 것으로 예상됩니다. 9.4% 연간).

고성장 수익: A001060 의 수익(연간 10.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: A001060 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 22.2 %)

JW Pharmaceutical 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 22% to ₩40,163

Price target increased by 7.7% to ₩36,245

Price target decreased to ₩33,000

Price target increased to ₩40,000

Recent updates

JW Pharmaceutical's (KRX:001060) Solid Earnings May Rest On Weak Foundations

Dividend of ₩392 announced

New minor risk - Shareholder dilution

JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly

Investor sentiment deteriorates as stock falls 22%

First quarter 2024 earnings released: EPS: ₩816 (vs ₩643 in 1Q 2023)

Now 21% overvalued

JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality

Full year 2023 earnings: EPS misses analyst expectations

Now 21% overvalued after recent price rise

Price target increased by 22% to ₩40,163

Investor sentiment improves as stock rises 17%

New minor risk - Earnings quality

Investor sentiment improves as stock rises 21%

New minor risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued

Investor sentiment improves as stock rises 19%

Price target increased by 7.7% to ₩36,245

New minor risk - Share price stability

Investor sentiment improves as stock rises 24%

Full year 2022 earnings released: EPS: ₩1,331 (vs ₩41.00 loss in FY 2021)

Upcoming dividend of ₩375 per share

No independent directors

Price target decreased to ₩33,000

Price target increased to ₩40,000

No independent directors

Upcoming dividend of ₩316 per share

Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?

Full year 2020 earnings released: ₩676 loss per share (vs ₩1,158 loss in FY 2019)

How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?

Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?

JW Pharmaceutical Corporation, Annual General Meeting, Mar 26, 2021

New 90-day low: ₩30,550

JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.

New 90-day high: ₩36,200

Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend

New 90-day high: ₩36,500

Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?

Third quarter 2020 earnings released: EPS ₩134

New 90-day low: ₩31,950

New 90-day high: ₩40,800

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견